Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program

Share this
Jazz Pharmaceuticals


Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program


  • Jazz Pharmaceuticals has entered into a definitive agreement with Redx Pharma to acquire the latter’s KRAS inhibitor program incl. G12D selective and pan-KRAS molecules. Jazz will perform clinical, regulatory, manufacturing & commercialization activities
  • As per the agreement, Redx will obtain $10M upfront for the rights, patents & title for KRAS inhibitor programs, a payment of $870M on achieving development, regulatory & commercial milestones with an additional milestone of IND clearance plus tiered, mid-single-digit percentage sales-based royalties
  • Under a separate collaboration agreement, Redx will obtain payment for research and preclinical development for completing IND-enabling studies of both KRAS programs

Ref: Jazz Pharmaceuticals  | Image: Jazz Pharmaceuticals 

Related News:- Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions